Keyphrases
Phosphatase
100%
Trastuzumab
100%
AKT1
100%
PIK3CA
100%
P70S6K
100%
Tensin Homolog
100%
HER2-positive Metastatic Breast Cancer
100%
Survival Time
33%
Phosphoinositide 3-kinase Pathway
33%
Pathway Activation
22%
Poor Response
22%
PIK3CA mutation
22%
Trastuzumab Resistance
22%
Tumor
11%
Estrogen Receptor
11%
Chemotherapy
11%
Patient Outcomes
11%
Immunohistochemistry
11%
Targeted Therapy
11%
Tumor Response
11%
Metastatic Breast Cancer
11%
Phosphoinositide 3-kinase (PI3K)
11%
Downstream Signaling
11%
Direct Sequencing
11%
Mutation Status
11%
Primary Tumor Tissue
11%
Progesterone Receptor Negative
11%
HER2 Overexpression
11%
HER2-overexpressing Breast Cancer
11%
Pharmacology, Toxicology and Pharmaceutical Science
Trastuzumab
100%
Metastatic Breast Cancer
100%
Phosphatase
100%
Tensin
100%
Phosphatidylinositol 3 Kinase
36%
Survival Time
27%
Neoplasm
18%
Breast Cancer
9%
Estrogen Receptor
9%
Primary Tumor
9%
Chemotherapy
9%
Progesterone Receptor
9%
Biological Marker
9%
Biochemistry, Genetics and Molecular Biology
Phosphatase
100%
Tensin
100%
Trastuzumab
100%
Phosphoinositide 3-Kinase
36%
Survival Time
27%
Progesterone Receptor
9%
Estrogen Receptor
9%
Neuroscience
Phosphatase
100%
Trastuzumab
100%
Tensin
100%
Phosphoinositide 3-Kinase
36%
Immunohistochemistry
9%
Estrogen Receptor
9%
Progesterone Receptor
9%
Immunology and Microbiology
Trastuzumab
100%
Survival Time
27%